Dr. T. E. Allsopp has 14 years combined experience as a cell & molecular biologist, with particular interest in neurobiology. Published papers include the topics of neural cell fate specification, programmed cell death regulation in the nervous system and acute, chronic nervous system disease. After 12 years as a leading academic with a developing interest in the biology of stem cells he joined Stem Cell Sciences Ltd to utilize pluripotent, embryonic stem cells to discover unique human disease treatment and cures. As a senior scientist with SCS Ltd, he has gained valuable research experience in the basic biology, growth, regulated differentiation, engineering & technology application of murine embryonic stem cells (ES cells). A combination of industrial sponsored academic research & biotech experience have also provided a detailed knowledge base that facilitates the current commercial exploitation of stem cell technology in pharmaceutical R&D. Current responsibilities include directing the research in ES biology, development of ES-based technologies for applications in gene & drug discovery and business development.

Mark Bale PhD is Deputy-Director of Scientific Development and Bioethics in the UK Department of Health. Mark oversaw the 2005 UK Stem Cell Initiative and Government response as part of his has overall responsibility for domestic and international policy on cloning and stem cells. He is currently involved in the revision of the 1991 Human Fertilisation and Embryology Act. His group also has responsibility for NHS genetics services and the development of cell and gene based therapies. It is also responsible for national and international activities on bioethics, including representation at the United Nations, Council of Europe, UNESCO and OECD. Mark has a research background in microbial genetics and joined the Department of Health in 1999 after working on the occupational safety of GMOs and pathogens.

Mr. Bonfiglio was one of the early investors in the field of stem cells & regenerative medicines. From 2000-2005 he was a Senior Partner with Anthem Venture Partners, a $100 million early-stage technology venture capital firm. Anthem funded Advanced Cell Technology in 2000, and Mr. Bonfiglio led the team that took the Company public in early 2005 (ACTC.OB). While at Anthem, Mr. Bonfiglio led investments in both biotechnology and IT deals. He was responsible for managing Anthem's investments in Advanced Cell Technology, Corus Pharma, Nextest Systems, and Pulse Entertainment. Anthem has generated top quartile returns for its investors. Mr. Bonfiglio has over 25 years experience working with technology companies. Prior to joining Anthem, he was a Partner with Morrison & Foerster, where he worked extensively with technology clients. Mr. Bonfiglio was an Adjunct Professor of Law at Stanford Law School , from 1996 to 2000. Since 1995, he has been a regular Guest Lecturer at the Haas Business School , in UC Berkley. Mr. Bonfiglio was born in Detroit , Michigan in 1952. He received his B.A. in Mathematics (magna cum laude) from Michigan State University in 1975, and his J.D. (magna cum laude) from the University of Michigan Law School in 1981.

Dr. Gabriela Cezar, DVM, Ph.D., recently joined University of Wisconsin-Madison and the Wisconsin Stem Cell Research Program as an Assistant Professor in the department of Animal Sciences. Her laboratory focuses on ES cell applications in predictive toxicology and safety aspects of cell-based therapies. Previously, she served as Principal Scientist at Pfizer Global Research and Development, where she researched and developed stem cell-based platforms applicable to drug discovery and development. Her research focused more specifically on in vitro models for obesity, neurodegeneration and drug safety. She was also involved in generation of knockout and transgenic mice for in vivo target validation. Prior to the pharmaceutical industry, Dr. Cezar practiced as a veterinarian and researched cellular plasticity, epigenetic reprogramming and placental abnormalities in nuclear transfer animals at Infigen Inc. (USA) and Roslin Institute (UK).

Dr Choo is the Founder and Chief Executive of Plasticell. He was a Founder and Chief Scientist of Gendaq Ltd, an MRC gene regulation company which was acquired by US biotech Sangamo Biosciences Inc. (Richmond, CA). Previously Dr Choo was a staff scientist at the MRC Laboratory of Molecular Biology, Cambridge. He is an inventor named in over 15 granted patents and has published over 30 scientific papers, holds a PhD in Molecular Biology from the University of Cambridge and is the recipient of the Prize for Young Scientists awarded by Pharmacia Biotech and Science the pre-eminent international scientific journal.

Following PhD training in Neuroendocrinology at St. Thomas's Hospital Medical School in London, Aaron studied the molecular regulation of gene expression in the pituitary gland at INSERM in Paris. This led to research on G Protein-Coupled Receptor Kinases at the Mario Negri Institute in Italy, where his work shed light on the disease implications of these kinases. Subsequently Aaron joined GlaxoWellcome in 1996 to apply this expertise towards drug discovery in respiratory diseases. After the formation of GlaxoSmithKline in 2001, Aaron moved into drug discovery for CNS diseases, and has led programmes in early and late preclinical stages for Alzheimer’s Disease. During the same period he initiated a stem cell research programme for neurodegenerative diseases. Aaron is also involved in international business development opportunities, and serves on the editorial board for Regenerative Medicine.

Dr. Craig joined Progenitor Cell Therapy, LLC as Chief Technology Officer & Vice President in July 2005. Prior to joining PCT, Dr. Craig served as Chief Operating Officer at Xcyte Therapies, Inc., a company developing T cell-based therapeutic products for the treatment of cancer, immune dysfunction and other diseases. Over the course of six (6) years at Xcyte Therapies, Dr. Craig designed, built, validated and operated both pilot-scale and commercial-scale facilities for the GMP manufacture of T-cell based products and managed the departments responsible for process development, assay methods development, manufacturing operations, quality control, quality assurance, regulatory affairs and external contract manufacturing of antibodies and antibody coated beads. Dr. Craig was also responsible for various business development activities in the US, Europe and Asia and participated in the multiple private and public funding efforts of Xcyte Therapies, including the S1 compilation, the successful IPO road show and the subsequent secondary public offering road show. Prior to joining Xcyte Therapies, Dr. Craig served as Vice President, Development & Operations at Osiris Therapeutics the Baltimore-based mesenchymal stem cell therapy company. In this role Dr. Craig built the development and manufacturing infra-structure for Osiris that was integral to the initiation of clinical trials, including the design, construction, validation and operation of a pilot-scale GMP manufacturing facility. Designs for a commercial-scale GMP manufacturing facility were also successfully presented and vetted by FDA. During this time Dr. Craig was also a member of the United States Pharmacopeia Expert Advisory Panel for Cell and Gene Therapy and was a co-authored for the initial USP monograph on this subject. From 1994 - 1996, Dr. Craig served as Vice President Product & Process Development at SyStemix, Inc., the pioneering Califonia-based hematopoietic stem cell and gene therapy company. From 1987 – 1993, Dr. Craig served in various research and development positions at British Biotech, PLC, working on the design, purification and characterization of recombinant therapeutic protein molecules. Dr. Craig received his B.Sc. in Biochemistry and Ph.D. in Physical Biochemistry from the University of Newcastle upon Tyne, UK.

Ivor Elrifi, Ph.D., LL.B. is co-chair of the Intellectual Property Section at Mintz Levin. He also is a member of the Policy Committee. Today Ivor advises biotechnology, life sciences and medical device companies, research institutions, universities, hospitals and governments throughout the world. He works with clients in several European countries, including Ireland, the U.K., Denmark, Germany and Switzerland. Ivor's practice includes patent prosecution, litigation, arbitration, licensing and transactional work. Ivor assists clients in developing and implementing worldwide patent strategies and in the prosecution and licensing of patents themselves. He currently is advising a number of leading genomics and proteomics companies located inside and outside the U.S. Ivor also becomes involved in transactional work for clients. He assists in conducting due diligence investigations with respect to investments, mergers and acquisitions. He has extensive experience in representing plaintiffs and defendants in patent litigation and arbitration cases. Ivor has recently lectured at Brown University, Harvard Medical School, and the Center for Gene Therapy and Surgical Research, Switzerland. He has also spoken at numerous international conferences, and has written articles for leading legal and scientific publications.

Michael Hunt, Chief Executive Officer, has been a director of ReNeuron since January 2001. He joined ReNeuron as Chief Financial Officer, and was appointed Chief Operating Officer in September 2003 and Chief Executive Officer in July 2005. Prior to ReNeuron, he spent six years at Biocompatibles International plc, where he held a number of senior financial and general management positions. His early industrial career was spent at Bunzl plc. Mr Hunt studied economics at University College London and qualified as a chartered accountant with Ernst & Young in London.

COO of Cellartis since 2003. Johan served as CEO of Cellartis 2001-2003. Johan holds a Ph.D. in reproductive physiology and has experience in advanced industrial developmental biology research (Hoffmann LaRoche). Furthermore, he has gained extensive experience in business development and management as a senior manager in a biotech company (Vitrolife AB). His experience also includes successfully starting, developing, and divesting start-ups.

Dr Kadouri is the chairman of ACTIP European Animal Cell Technology Industrial Platform and a member of Scientific Advisory Boards of several European and American companies and also a consultant to many biotech companies. Prior to his forming Rainbow Biotechnologies he was bioprocess Technology Development Director, Serono Biotech Center, Vevey, Switzerland.

Paul Kemp has been heavily involved in commercial Tissue Engineering for the last 17 years both in the U.S. and the U.K. After post-doctoral research on the biochemistry of collagen cross-links at Manchester University, he joined Organogenesis Inc in late 1986. Boston based Organogenesis is the world’s first Tissue Engineering company and while there Paul was instrumental in the commercial development of Apligraf which was to become the FDA’s first approved manufactured human organ and is currently used in the U.S. for the treatment of chronic wounds. During his time at Organogenesis, Paul was heavily involved in all aspects of the pioneering of this new area of medicine and taking on several different rolls eventually becoming a Vice President. Paul left Organogenesis in 1997 to return to the UK and founded Intercytex in 1999. This company is devoted to the cellular induction of human tissues and organs and has products in hair and skin regeneration that are undergoing clinical studies. Paul has published on Tissue Engineering and holds several patents relating to tissue engineered tissues and organs. He has so far developed three different cell-based products that have undergone successful clinical trials in North America and Europe. Paul has raised over £20 million pounds in venture capital for Intercytex and the company was voted BioNow’s Biotechnology company of the year in 2003/4.

Dr. Eric Lagasse is an associate professor in the Department of Pathology and the Director of the Cancer Stem Cell Center. In 1985, he received his Diplôme d’Etat de Docteur en Pharmacie from University of Strasbourg, France and in 1989 he completed his Ph.D. in Microbiology from the University of Basel, Switzerland. From 1989 to 1997, Dr. Lagasse was in the Department of Developmental Biology and Pathology, Stanford University. Dr. Lagasse served as the Director, Liver Stem Cell Discovery Program at StemCells Inc, Palo Alto, CA. from 1997 until he joined the McGowan Institute in July 2004.

James specialises in the law relating to reproductive and genetic technologies, and human tissue. He advises a large number of clinics and research centres licensed by the Human Fertilisation and Embryology Authority (HFEA) and has been involved in most of the leading cases relating to assisted reproduction and related research. James has advised widely on the regulatory and commercial issues relating to embryo and embryonic stem cell research, including patenting, cell nuclear replacement, import and export, and the implications of EU law. James is also a lecturer in Medicine and Law at the Institute of Human Genetics, the University of Newcastle.

Alan J. Lewis, Ph.D., joined Novocell in February 2006 as President, Chief Executive Officer, and Director. Prior to Novocell, Dr. Lewis served as CEO and Director of Signal Pharmaceuticals before its acquisition in 2000 by Celgene, a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for cancer and immunological diseases. He then served as President of the Signal Research Division at Celgene. Dr. Lewis previously held the position of Vice President of Research at Wyeth-Ayerst, where he spent 15 years leading research efforts in diabetes, CNS, cardiovascular, inflammatory, allergy, and bone metabolism diseases. Dr. Lewis currently serves as a Director of BioMarin Pharmaceutical, Inc., and Cytochroma, Inc. He holds a Ph.D. in pharmacology from the University of Wales in Cardiff and completed his postdoctoral training at Yale University.

Nicolas L'Heureux has been an early proponent of the concept of completely biological tissue engineering even for tissues that play significant mechanical roles. At a time when synthetic scaffolds were seen as a defining part of any tissue engineered construct, he developed a method termed “Sheet-Based Tissue Engineering” that allows the creation of completely biological, living, autologous and human tissues that display remarkable mechanical strength without the need for any exogenous scaffolding. In 2000, he founded Cytograft Tissue Engineering to develop this platform technology. Focusing first on vascular products, the Company started the world’s first clinical trial of a tissue-engineered blood vessel for arterial bypass. His research interests revolve around cell-based therapies and personalized medicine in the vascular field but also include pediatrics, neuroregeneration, orthopedics and vascular networks.

Geoff MacKay has served in his current leadership role since Dec. 2003. Mr. MacKay provides Organogenesis Inc. with significant global, commercial experience spanning the pharmaceutical and biotechnology sectors. Mr MacKay has held numerous leadership positions within Novartis AG in roles such as Vice-President & Business Unit Head, Transplantation & Immunology at Novartis Canada, Vice-President of Tissue-Engineering in Novartis USA, Head of Global Sales Immunology & Transplantation based in Basel, Switzerland, and prior to that as Sales & Marketing Manager of Novartis Biotech Europe. Mr MacKay has been specifically involved in the emerging field of Tissue Regeneration for the last decade.

Ram Mandalam, Ph.D., our President & CEO, joined the company in 2005. Ram was previously Executive Director of Product Development at Geron Corporation, where he managed the development and manufacturing of cell based therapies for treatment of degenerative diseases and cancer. Prior to Geron, he was Director of Developmental Research at Aastrom Biosciences, where he was responsible for the research and development programs involving ex vivo expansion of human bone marrow stem cells and dendritic cells. Dr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan. Dr. Mandalam is the author or co-author of several publications, patent applications, and abstracts.

Dr. Margolin has been serving on the Board of Directors of Gamida Cell since 2000. Prior to her employment as President & CEO of Gamida Cell, Dr. Margolin spent six years as Vice President of Denali Ventures LLC, where she specialized in investments in pharmaceutical and biotechnology companies. Dr. Margolin spent seven years at Teva Pharmaceuticals, where she was responsible for new product initiatives, evaluation of investment opportunities for the R&D division, and multiple drug development programs. Dr. Margolin holds a Ph.D. in Biochemistry from the Weizmann Institute of Science and was a post-doctoral associate at the Yale University School of Medicine.

Chris is at the forefront of the emerging field of regenerative medicine bioprocessing plus is involved in a number of committees, working groups and initiatives related to both the academic and commercial advancement of stem cells and tissue engineering. Originally graduating from Imperial College (Molecular Biology) and St. Thomas’s Hospital Medical School (Medicine) and then specialising in surgery - Fellow of the Royal College of Surgeons. In addition, Chris has a PhD in Biochemical Engineering (UCL), leads the Regenerative Medicine Bioprocess Group at UCL and has broad range of expertise in industrial consultancy. Furthermore, Chris has over ten years experience at boardroom level of running technology companies and is co-organiser of the London Regenerative Medicine Network.

John McNeish is Senior Director in Pfizer Global Research and Development in Groton CT and Head of the Center of Excellence for Genetically Modified Models that includes responsibilities for research and application in stem cell technologies. Prior to joining Pfizer in 1992, he received his PhD from the University of Cincinnati in Developmental Biology with Dr. S. Steven Potter and completed post-doctoral research focusing in murine ES cell technology with Dr. Oliver Smithies at the University of North Carolina. He has co-authored more than 40 articles and book chapters on the use of genetically modified mice and stem cells.

C. Randal Mills, Ph.D., President and Chief Executive Officer, joined Osiris in July 2004. Dr. Mills is also a member of the Board of Directors. Prior to joining Osiris, Dr. Mills was an executive officer of Regeneration Technologies, Inc. (NASDAQ—RTIX). Dr. Mills served in several leadership positions at RTI from its formation in 1998 until 2004, including Vice President of Business Development and Vice President of Operations and R&D and is credited with several key initiatives including the development and commercialization of RTI’s core technology, BioCleanse®. Prior to RTI, Dr. Mills was a member of the founding management team of the University of Florida Tissue Bank, Inc. The University of Florida Tissue Bank was the predecessor company to RTI. Dr. Mills received a Bachelors degree in microbiology and cell science and a Ph.D. in drug development, both from the University of Florida.

Dr Stephen Minger is the Director of the Stem Cell Biology Laboratory and a Senior Lecturer in the new Wolfson Centre for Age Related Diseases at King's College London. Dr Minger received his PhD in Pathology (Neurosciences) in 1992 from the Albert Einstein College of Medicine. From 1992-1994, he was a post-doctoral fellow in the laboratory of Professor Fred Gage, University of California, San Diego, where he first began to pursue research in neural stem cell biology. Additional post-doctoral training was obtained at the University of Kentucky, and in 1995, Dr Minger was appointed an Assistant Professor in Neurology at The University of Kentucky Medical School. He moved his stem cell research programme to Guy’s Hospital in 1996 and was appointed a Lecturer in Biomolecular Sciences at King's College London in 1998. Over the last 13 years, his research group has worked with a wide range of somatic stem cell populations, as well as mouse and human embryonic stem (ES) cells. In 2002, together with Dr Susan Pickering and Professor Peter Braude, Dr Minger was awarded one of the first two licenses granted by the UK Human Fertilisation and Embryology Authority for the derivation of human ES cells. His group subsequently generated the first human embryonic stem cell line in the UK and was one of the first groups to deposit this into the UK Stem Cell Bank. They have gone on to generate three new human ES cell lines, including one that encodes the most common genetic mutation resulting in Cystic Fibrosis. Dr Minger’s research is supported by the UK Medical Research Council, The Juvenile Diabetes Research Foundation International, The Oliver Bird Foundation, The Wellcome Trust, The UK Department of Trade and Industry, The Charitable Foundation of Guy’s and St Thomas’ Hospitals, the BBSRC, and the EPSRC amongst others.

Gail K. Naughton, Ph.D., has been the Dean of the College of Business Administration at San Diego State University since August 2002. Prior to that, she spent more than 15 years at Advanced Tissue Sciences, where she was the company’s co-founder and co-inventor of its core technology. During her tenure there, Dr. Naughton held a variety of key management positions, including president. While serving as an officer and director of the Company, Dr. Naughton oversaw the design and development of the world’s first up-scaled manufacturing facility for tissue engineered products, established corporate development and marketing partnerships with companies including Smith & Nephew, Ltd., Medtronic and Inamed Corporation, was pivotal in raising over $350M from the public market and corporate partnerships, and brought four fibroblast-based products from concept through FDA approval and market launch. Dr. Naughton holds over 90 U.S. and foreign patents and has been extensively published in the field of tissue engineering. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering. Dr. Naughton has continued her research in cell based products for the last 5 years and in June of 2007 founded Histogen, a regenerative medicine company focused on insoluble human extracellular matrix proteins and soluble protein products manufactured by human neonatal fibroblasts under embryonic (hypoxic) conditions.

Thomas B. Okarma, Ph.D., M.D. was appointed President and Chief Executive Officer of Geron in July, 1999. Dr. Okarma served as Vice President of Research and Development of the Company since May 1998. From December 1997 until May 1998, Dr. Okarma was Vice President of Cell Therapies. Prior to joining the Company in 1997, Dr. Okarma was a senior Vice President at Rhone-Poulenc Rorer. In 1995, Rhone-Poulenc Rorer acquired Applied Immune Sciences, Inc. (AIS) which was founded by Dr. Okarma in 1985. By the time of its acquisition by Rhone-Poulenc Rorer, AIS was in advanced cell therapy human clinical trials in cancer and bone marrow transplantation and in early gene therapy human trials in breast cancer. Dr. Okarma was Chairman and Chief Executive Officer of AIS. Prior to founding AIS, Dr. Okarma was a member of the faculty of the Stanford University School of Medicine. Dr. Okarma received both his Ph.D. and M.D. from Stanford University. He is the author of over 50 publications on cell and gene therapy and is an inventor on numerous patents in the field.

Dr Riddell was appointed Chief Executive Officer of Stem Cell Sciences in November 2007. As a longstanding bioentrepreneur with more than 24 years experience in the industry, Dr Riddell spent considerable time at Board level building companies, raising money and negotiating corporate deals. From 2006 to 2007 he held the position of Non Executive Chairman at Surface Therapeutics prior to its sale to Serentis in September 2007. From 2005, he was Chief Executive Officer of Paradigm Therapeutics where he achieved a successful trade sale to Takeda Pharmaceutical Corporation in March 2007. Prior to Paradigm, Dr Riddell was Chief Executive Officer of Pharmagene for 7 years, during which time he successfully listed the company on the main market of the London Stock Exchange. He has also held senior positions with Celltech, Centocor and Amersham International in clinical development before moving to sales and marketing. Dr Riddell began his professional career as a medical doctor with six years experience in a variety of hospital specialties and in general practice. He is an active Board member of the BIA, a position he has held from 2000 to 2006 and recently re-elected to serve for the 2008 term. In November 2007 Dr Riddell joined the Board of Sareum Holdings plc as Non Executive Director.

William Schwieterman is an independent consultant for biotech and pharmaceutical companies who specializes in clinical development. Dr. Schwieterman is a board-certified internist and rheumatologist who spent 10 years at the FDA in the Center for Biologics overseeing a wide range of clinical development plans for a large number of different types of molecules. First as Chief of the Medicine Branch, and then as Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials in CBER, he worked with sponsors for the development of new agents for pulmonary medicine, neurology, sepsis, hepatitis, rheumatology, infectious disease, solid organ transplantation and wound-healing, among other areas, and also worked closely with reviewers of vaccines, devices (CDRH) and oncologic products. Dr. Schwieterman also helped author the Agency’s “Good Review Practices” for investigational products—and was instrumental in the development of several guidance documents. He currently resides in Mobile, Alabama with his wife and three children.

Michael Siani-Rose, President and Founder, has 15 years of biotechnology experience. He has extensive experience in the computational chemistry and drug discovery fields, including managerial and scientific positions at Protos/Chiron Corporation, Kosan Biosciences and Affymetrix. Michael has published 35 peer-reviewed articles, is inventor on five patents in the field of drug discovery/drug design, and has a dozen patent applications in the fields of bioinformatics and tissue engineering.

Bernard Siegel is the full-time Executive Director of the nonprofit Genetics Policy Institute (GPI) based in Wellington, Florida. He received his undergraduate and law degrees from the University of Miami (BA 1972, JD 1975). He is a member of the Florida Bar since 1975. Through GPI, Mr. Siegel has worked to expand, the Student Society for Stem Cell Research, which in a period of 3 years has grown into an education and advocacy organization having a presence in 15 countries, 35 states, 100 institutions and more than 25 active chapters at universities around the country. Mr. Siegel is the vice-president of Floridians for Stem Cell Research and Cures, which seeks to place $200 million of funding for embryonic stem cell research on the Florida ballot in 2008.

Dr. Snodgrass founded VistaGen in 1998 and has been its CEO since inception. Prior to VistaGen, he was Chief Scientific Officer of Progenitor, Inc., where he was the primary architect of the discovery platform that was the basis for equity investments and corporate alliances valued at over $100 million, all leading to the company’s successful IPO. Dr. Snodgrass has a Ph.D. from the University of Pennsylvania and has over 10 years experience in senior management in entrepreneurial biotechnology companies, and over 10 years research experience as a professor at the Lineberger Comprehensive Cancer Center, University North Carolina Chapel Hill School of Medicine, and as a member of the Institute for Immunology, Basel, Switzerland.

Alan Trounson, Ph.D., is currently President of the California Institute for Regenerative Medicine. Professor Trounson was previously Professor of Stem Cell Sciences and Director of Monash Immunology and Stem Cell Laboratories at Monash University. He was the Founder of the National Biotechnology Centre of Excellence – ‘Australian Stem Cell Centre’. His scientific accomplishments include; the pioneering of human in vitro fertilisation (IVF) and associated reproductive technologies; the diagnosis of inherited genetic disease in preimplantation embryos; the discovery and production of human embryonic stem cells and their ability to be directed into neurones, prostate tissue and respiratory tissue. He is on the Victorian Government’s Innovation Economy Advisory Board, and is a Director of the Victorian Endowment for Science, Knowledge and Innovation (VESKI). His present research interests are focused on the formation of human embryonic stem cells and stem cell biology; reprogramming pluripotentiality by cytoplasmic and nuclear transfer; embryonic stem cell differentiation into respiratory, thymic, prostate and gametic lineages; and adult and embryonic stem cell utilization in cell therapy for inflammatory lung disease and cystic fibrosis.

Dr Michael West is the Chief Executive Officer of Biotime Inc., a regenerative medicine company expanding its commercialization focus to include stem cell technology. Under the leadership of Dr Michael West, who pioneered this industry after he founded Geron Corporation and later during his tenure at Advanced Cell Technology, BioTime intends to become a significant biotechnology company in this emerging sector, focusing on near-term commercialisation opportunities.

Gareth is a Chartered Patent Attorney, European Patent Attorney and European Trade Mark Attorney. He has acted for clients in a variety of fields with particular expertise in patent work in the fields of biotechnology, medical devices, business method inventions and mechanical devices. His practice involves the drafting, filing and prosecution of patent applications worldwide, the handling of opposition and appeal work at the European Patent Office, and advice on infringement matters and general intellectual property strategy. Gareth obtained an honours degree in biological sciences from Oxford University, and then stayed on to do a doctorate in molecular biology and genetics researching the Y chromosome, funded as part of the Human Genome Project.